钠-葡萄糖共转运蛋白2抑制剂类药物在心力衰竭患者合并心律失常中的研究进展

[Abstract]With the widespread clinical application of sodium-glucose cotransporter 2 inhibitors （SGLT2i）， an increasing numberofstudieshave highlightedtheirbeneficialefects notonlyinbloodglucosecontrolindiabetic patients but also in providing significant cardiovascular protection in non-diabetic individuals，particularly those with heartfailure.These drugscansignificantlyreduce theoccuenceof arrhythmias through multiple mechanisms. Currently marketedSGLT2i drugs，including Dapagliflozin，Empagliflozin，andCanagliflozin，havebeenreportedto be beneficial inarrhythmic patients.Their mechanisms of action involvemodulationof ionchannels，enhancement of cardiacenergyutilization eficiency，andreductionoffatyacidaccumulation，among others.Thisreviewaims to analyze theroleofSGLT2i intheprevention and treatmentof arhythmiasand their underlying mechanisms by reviewing the relevant literatureinrecent years，and to provideareference for future studiesto clarifythe potential applications of SGLT2i in various arrhythmia types.

[Keywords] Sodium-glucose cotransporter 2 inhibitorsHeart failureArrhythmia

First-author'saddress：Departmentof Cardiology，Jinan ThirdPeople'sHospital，Jinan250100 China

doi：10.3969/j.issn.1674-4985.2025.21.040

心力衰竭（heartfailure，HF）作为一种较为常见的临床综合征，常由各种心脏疾病引起，主要特征表现为心脏泵血功能下降，并伴随多种心脏电生理异常，这其中，以心律失常，尤其是室性心律失常（ventriculararrhythmia，VA）为最常见的一种并发症，同时，其也是导致心源性猝死（suddencardiacdeath，SCD）和住院率增加的重要因素[-2]。（剩余8764字）